Large-Scale Intranasal COVID-19 Vaccine Trial to Involve 10,000 Participants

The phase 2b study, which will begin in the fall of 2024, will evaluate the vaccine in a subset of participants at a higher risk of severe disease.

TopMicrobialStock/Shutterstock

University of Georgia-based startup CyanVac LLC received $40 million in federal funding on Wednesday to launch its intranasal COVID-19 vaccine clinical trial.

According to a University of Georgia (UGA) press release, CyanVac will sponsor a randomized, double-blind phase 2b study with 10,000 participants to compare the vaccine’s efficacy and safety against an FDA-approved mRNA-based COVID-19 vaccine.